Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease.
Hellmann, J; Etter, RK; Denson, LA; Minar, P; Hill, D; Dykes, DM; Rosen, MJ.
Pediatric Quality and Safety.
2021;
6.
Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
Colman, RJ; Portocarrero-Castillo, A; Chona, D; Hellmann, J; Minar, P; Rosen, MJ.
Inflammatory Bowel Diseases.
2021;
27:507-515.
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
Lyles, JL; Mulgund, AA; Bauman, LE; Su, W; Fei, L; Chona, DL; Sharma, P; Etter, RK; Hellmann, J; Denson, LA; et al.
Inflammatory Bowel Diseases.
2021;
27:482-492.
Neurologic Complications due to Severe Micronutrient Deficiencies in an American Adolescent.
Lyles, JL; Hellmann, JA; Oliveira, SB.
Nutrition in Clinical Practice.
2020.
A Micro-longitudinal Approach to Measuring Medication Adherence in Pediatric Inflammatory Bowel Diseases.
Plevinsky, JM; Denson, LA; Hellmann, J; Minar, P; Rosen, MJ; Hommel, KA.
Journal of Pediatric Gastroenterology and Nutrition.
2020;
71:366-370.
Microbial Shifts and Shorter Time to Bowel Resection Surgery Associated with C. difficile in Pediatric Crohn's Disease.
Hellmann, J; Andersen, H; Fei, L; Linn, A; Bezold, R; Lake, K; Jackson, K; Meyer, D; Dirksing, K; Bonkowski, E; et al.
Inflammatory Bowel Diseases.
2020;
26:1212-1221.
303 – Effect of a Practice-Wide Anti-TNF Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
Lyles, JL; Mulgund, AA; Bauman, LE; Su, W; Fei, L; Chona, D; Sharma, P; Etter, R; Hellmann, J; Denson, LA; et al.
Gastroenterology.
2019;
156:s-60.
C. difficile Infection in Children: What’s New?.
Hellmann, J; Mallon, D.
Current treatment options in pediatrics.
2018;
4:255-269.